Formulation And Evaluation Of Mucoadhesive Microspheres Of Anti Asthmatic Agent For Nasal Delivery

Abstract

Drug delivery methods that allow for prolonged, close contact between the drug and the mucosa are known as mucoadhesive drug delivery systems. In order to prevent hepatic first-pass metabolism, increase residence time, and improve therapeutic efficacy, the current study aimed to produce mucoadhesive microspheres for nasal delivery. In our work, we used the Emulsification cross linking approach  to create salbutamol mucoadhesive microspheres with conjugation of chitosan. The microspheres were assessed in terms of their stability, in vitro drug release, in vitro mucoadhesion, yield, particle size, entrapment efficiency, and swelling property. Using scanning electron microscopy and infrared spectroscopy, microspheres were characterised.  Each batch's average microsphere particle size varied from 10 to 50.6 µm, ensuring that every batch had appropriate handling qualities. It was discovered that the range of drug encapsulation efficiency for all formulations was 80.75% to 90.87%. It was discovered that the medication yield percentage for each formulation ranged from 86.11 to 93.87. Mucoadhesion percentages were observed to range from 53.23% to 85.87%. When all of the formulations were tested for drug release in vitro using phosphate buffer pH 6.8, microspheres showed regulated drug release for up to six hours. According to the results gathered, mucoadhesive microsphere preparation procedures represent a very promising nasal delivery technology for improving patient compliance and delivering medication over an extended period of time.